Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration’s (FDA) Orange Book upon the ...
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
The FDA communicated that it has applied a standard three-month extension from the original goal date of February 28, 2025. Eton believes it has fully addressed all questions from the FDA and there ...
WPRI 1227d
Collaborations Pharmaceuticals, Inc. Provides New Insights Into Metabolism of Chemical Warfare Nerve Agents In Humans
CEO of Collaborations Pharmaceuticals, Inc. “The results of this work could contribute to the understanding of which enzymes are involved and how they are removed from the human body or whether ...